Astellas

Ophthalmology specialist Iveric snapped up by Astellas for $5.9 billion

03-May-2023 By Jonathan Smith

The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.

Astellas to create $70m biotech campus in San Francisco

25-Jul-2022 By Rachel Arthur

Astellas Pharma Inc. will build a biotechnology campus in South San Francisco: providing capabilities to develop cell and gene therapies.

Mogrify and Astellas align to tackle hearing loss

05-Jul-2022 By Jane Byrne

Cambridge, UK based Mogrify Limited is teaming up with Japan’s Astellas Pharma in targeted research aimed at addressing sensorineural hearing loss.

Astellas and CytomX team up to target solid tumors with T-cells

26-Mar-2020 By Ben Hargreaves

The two partners will work to develop clinical candidates for the treatment of cancer.

Audentes invests in large-scale gene therapy manufacture

19-Feb-2020 By Ben Hargreaves

Audentes augments its in-house production capacity with additional plans for a North Carolina facility.

Astellas continues to make deals, partnering with Adaptimmune

15-Jan-2020 By Ben Hargreaves

The newly established deal includes the co-development of up to three T-cell therapies, by utilizing the latter’s stem-cell derived allogeneic T-cell platform.

Astellas acquires Xyphos and its CAR-T technology for $665m

09-Jan-2020 By Ben Hargreaves

Astellas continues its acquisition spree in the advanced therapeutics space through a deal for Xyphos and its next-generation take on CAR-T therapies.

Pfizer eyes yield gains from doing gene therapy production in-house

09-Dec-2019 By Nick Taylor

Pfizer tips $500m investment in gene therapy plant to improve yield, purity and characterization.

Astellas in $3bn gene therapy acquisition, highlights manufacturing capabilities

04-Dec-2019 By Ben Hargreaves

Astellas agrees deal for Audentes, which has a pipeline of gene therapies and large-scale manufacturing capabilities.

Astellas taps into Pandion’s platform for bispecifics development

05-Nov-2019 By Vassia Barba

Astellas and Pandion join forces to develop treatments for autoimmune pancreatic diseases using the latter’s modular immune effector.

Astellas provides funding for US cell and gene therapy biotechs

03-Oct-2019 By Ben Hargreaves

Astellas to fund two biotech incubators, operated by LabCentral, to cultivate start-up companies focused on cell and gene therapies.

Hired and Retired: High profile exits to biotech

18-Jan-2019 By Ben Hargreaves

The numbers of high profile executives departing large pharma companies this month again emphasised the draw of working in the biotech industry.

Astellas invests $256m in cell therapy manufacturing buildout

07-Nov-2018 By Ben Hargreaves

The company will construct two facilities in Japan and relocate its regenerative medicine facility in the US.

Astellas prioritises ophthalmology with gene therapy acquisition

21-Aug-2018 By Ben Hargreaves

Astellas has announced that it will acquire Quethera and its gene therapy programmes for the treatment of glaucoma.